Screener
Capricor Therapeutics CAPR Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -73.7%+46.5pp | -56.4%+19.0pp | -46.6%+1.6pp | -107.8%— | -120.2%+273pp | |
| Return on invested capital | -67.7%+97.6pp | -83.2%+14.1pp | -128.7%-71.6pp | -206.8%— | -165.3%— | |
| Liquidity | ||||||
| Current ratio | 7.3×+3.0× | 8.4×+1.9× | 9×+1.2× | 3.6×-0.6× | 4.4×+3.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×+0.4× | 0.1×0.0× | 0×0.0× | 0.2×+0.1× | 0×-0.4× | |
| Per Share | ||||||
| Book value per share | $4.25+85.1% | $4.85+73.5% | $6.58+59.3% | $1.83-11.1% | $2.30+536% | |
| Valuation | ||||||
| Market capitalization | $519.76M+42.6% | $1.75B+303% | $1.57B+150% | $329.62M-38.7% | $422.8M+177% | |
| Price / book | 2.1×-2.2× | 6.3×+2.9× | 5.1×+0.8× | 3.9×-3.9× | 4×-9.2× |
FAQ
- Where do Capricor Therapeutics's ratios come from?
- Every ratio is computed from Capricor Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.